Article
ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
Cancer biology & therapy - 1 Jul 2009
Chen Jianfang, Xie Fangwei, Chen Keli, Wang Dong, Jiang Heng, Li Jianjun, Pan Feng, Chen Shixu, Zhang Yanling, Ruan Zhihua, Huang Haihui, Zou Lan, Liang Houjie
Abstract excerpt
This study aimed to investigate whether single nucleotide polymorphisms (SNPs) in the promoter of the excision repair cross complementation group 5 (ERCC5) gene influences response to oxaliplatin-based chemotherapy. Eighty-three patients with cytologically or histologically confirmed advanced colorectal cancer (CRC), at least one measurable lesion and underwent oxaliplatin-based chemotherapy were studied. To this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
